Several therapies targeting LAG‐3, including favezelimab, eftilagimod alpha, and relatlimab, are currently being assessed in recent clinical trials for first‐line treatment in advanced NSCLC. This evidence concerns the gene LAG3 and non-small cell lung carcinoma.